Applied Therapeutics Inc. - 10-K filing on 2022-03-10

STOCK BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2021

Stock-based compensation

Schedule of stock-based compensation expenses

Total stock-based compensation expense recorded for employees, directors and non-employees (in thousands):


		Year Ended
		December 31,
(in thousands)		2021			2020
Research and development		$	2,759		$	2,580
General and administrative			8,418			5,446
Total stock-based compensation expense		$	11,177		$	8,026

Schedule of options outstanding


							Weighted-Average
				Weighted-			Remaining		Aggregate
		Options		Average			Contractual		Intrinsic
(in thousands, except for share data)		Outstanding		Exercise Price			Term (in years)		Value
Outstanding at December 31, 2020		4,529,675		$	12.87		8.49		$	51,103
Options granted		406,752			13.74
Options exercised		(191,436)			2.67					2,990
Forfeited		(40,008)			21.43
Expired		(95)			44.02
Outstanding at December 31, 2021		4,704,888		$	13.29		7.7		$	10,305

Exercisable at December 31, 2021		3,168,679		$	9.83		7.3		$	10,258
Nonvested at December 31, 2021		1,536,209		$	20.40		8.6		$	48

Schedule of restricted stock units outstanding


				Weighted-Average
				Grant Date			Aggregate
(in thousands, except for share data)		Shares		Fair Value			Intrinsic Value
Outstanding at December 31, 2020		206,529		$	36.08		$	4,546
Awarded		348,536			11.03
Released		(52,562)			33.52
Forfeited		(33,018)			32.07
Outstanding at December 31, 2021		469,485		$	18.05		$	4,202
Nonvested at December 31, 2021		469,485		$	18.05		$	4,202

Weighted Average Remaining Recognition Period (in years)		3.4

Stock options - Service conditions only

Stock-based compensation

Schedule of valuation assumptions


		Year Ended
		December 31,
		2021			2020
Expected term (in years)			5.8			6.1
Volatility			71.92	%		69.70	%
Risk-free interest rate			1.08	%		0.51	%
Dividend yield			—	%		—	%